utomilumab + pembrolizumab

**Utomilumab + pembrolizumab** is a combination of two immunotherapy agents for use in cancer treatment. Utomilumab (PF-05082566) is a monoclonal antibody that acts as a 4-1BB (CD137) agonist, stimulating T cell activation and enhancing immune responses against tumors. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), blocking inhibitory signals to T cells and promoting anti-tumor activity. The combination is evaluated for advanced solid tumors, leveraging complementary mechanisms: utomilumab boosts T cell activity, while pembrolizumab removes immunosuppressive signals to increase anti-tumor responses. Both agents are biologics delivered via intravenous infusion. Early-phase studies show promising safety and anti-tumor activity, with ongoing investigation for efficacy across solid tumors[1][3].

Brand names

Keytruda

Other names

utomilumab + KeytrudaPF-05082566 + pembrolizumab